Motley Fool
2 Pharma Stocks With Blockbuster Drugs on the Horizon
AbbVie’s Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been the world’s top-selling drug for years. Now, Eli Lilly (NYSE: LLY) and Bristol Myers Squibb (NYSE: BMY) have blockbuster drugs in the works that could also change lives and boost their companies’ fortunes. Lilly’s Mounjaro (tirzepatide), a once-weekly injection, received its first Food and Drug Administration (FDA) approval in May as a therapy to treat type 2 diabetes, but the therapy also has huge potential as a weight-loss drug.